Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

BACKGROUND: Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy, improving outcomes in the treatment of various malignancies. However, not all patients benefit to the same extend from ICI. Reliable tools to predict treatment response and outcome are missing. Soluble ur...

Descripción completa

Detalles Bibliográficos
Autores principales: Loosen, Sven H., Gorgulho, Joao, Jördens, Markus S., Schulze-Hagen, Maximilian, Beier, Fabian, Vucur, Mihael, Schneider, Anne T., Koppe, Christiane, Mertens, Alexander, Kather, Jakob N., Tacke, Frank, Keitel, Verena, Brümmendorf, Tim H., Roderburg, Christoph, Luedde, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047604/
https://www.ncbi.nlm.nih.gov/pubmed/33869041
http://dx.doi.org/10.3389/fonc.2021.646883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047604/
https://www.ncbi.nlm.nih.gov/pubmed/33869041
http://dx.doi.org/10.3389/fonc.2021.646883

Ejemplares similares